Study: Tykerb plus Herceptin extends progression-free survival in advanced HER2-positive breast cancer

GlaxoSmithKline reported promising data from the first Phase III trial testing Tykerb (lapatinib) in combination with Roche's and Genentech's Herceptin (trastuzumab) in patients with HER2-positive metastatic breast cancer. The findings will be presented at the upcoming annual meeting of the American Society of Clinical Oncology.

In the Phase III trial, 296 patients with HER2-positive breast cancer, who had documented progression while taking Herceptin, were randomised to receive Herceptin plus Tykerb or Tykerb alone. The findings showed that those who received the combination therapy experienced a statistically significant increase in median progression-free survival of 12 weeks, compared with 8.1 weeks in those who took Tykerb only. In addition, those who were administered Tykerb plus Herceptin experienced a response rate of 10.3 percent, compared with 6.9 percent in the Tykerb-only group.

"Really blocking that pathway is an effective strategy. This gives us a new treatment option for patients," commented lead researcher Joyce O'Shaughnessy of the Baylor-Sammons Cancer Center in Dallas, Texas.

Earlier this week, GlaxoSmithKline initiated a late-stage study comparing Tykerb with Herceptin in early breast cancer.

To read more Top Story articles, click here.